News

DXC Technology Posts First Quarter Results for Fiscal 2026

DXC Technology Posts First Quarter Results for Fiscal 2026

DXC Technology Reports First Quarter Results

DXC Technology has shared its results for the first quarter of fiscal year 2026, highlighting a total revenue of $3.16 billion, which shows a decrease of 2.4% compared to the previous year. Moreover, when considering the organic aspects of the business, the revenue decline deepens to 4.3%. Despite these challenges, there are positive signs, particularly in bookings, which saw a 14% increase year over year, totaling $2.8 billion.

Financial Highlights

The financial performance metrics reveal crucial insights for stakeholders. The EBIT margin registered at 2.4%, while the adjusted EBIT margin reached a more encouraging 6.8%. This performance underlines DXC’s resilient operational strategies amidst adverse market conditions.

Earnings Performance

In terms of earnings per share (EPS), the diluted EPS was reported at $0.09, a notable decrease compared to $0.14 from the same quarter last year. However, non-GAAP diluted EPS stood at $0.68, marking a decline of 9.3% year over year.

Shareholder Returns and Strategy

DXC is committed to returning value to its shareholders. The company has repurchased shares worth $50 million, demonstrating its ongoing confidence in the business model and future prospects. This strategic move aims to enhance shareholder value and manage capital effectively.

CEO Insights

Raul Fernandez, President and CEO of DXC Technology, stated, "We delivered first quarter results at the high end of our guidance for both organic revenue growth and adjusted EBIT margin, with non-GAAP EPS exceeding expectations. For the third straight quarter, we reported double-digit bookings growth, a clear sign of our improved connection with clients. We are embedding AI in our solutions and leveraging our expertise to drive outcomes effectively. With a solid foundation, we are optimistic about our trajectory moving forward."

Segment Performance

Breaking down the various segments offers additional context to DXC's financial health:

  • Consulting and Engineering Services (CES): Generated $1,246 million in revenue, slightly down by 2.7% YoY, but profit declined significantly by 14.6% YoY to $105 million.
  • Global Infrastructure Services (GIS): Reported revenues of $1,600 million, with a decrease of 3.5% YoY, and segment profit of $97 million.
  • Insurance Services: Achieved a revenue increase of 5.4% YoY to reach $313 million, although segment profit fell by 25% to $33 million.

Looking Ahead: Guidance and Expectations

As the company looks ahead for fiscal year 2026, it has projected total revenue to fall between $12.61 billion and $12.87 billion. This projection indicates an expected decline of 5.0% to 3.0% on an organic basis. Additionally, DXC aims for an adjusted EBIT margin ranging from 7.0% to 8.0%, and the non-GAAP diluted EPS is estimated to be between $2.85 and $3.35.

Future Growth Initiatives

DXC is focused on enhancing its strategic initiatives that incorporate artificial intelligence across its offerings, aiming to drive efficiency and value for clients. The ongoing transformation strategies are expected to position DXC favorably in a competitive market, underpinning a robust operational future.

Frequently Asked Questions

What are the key financial metrics from DXC Technology's recent quarter?

DXC Technology reported a total revenue of $3.16 billion, with diluted EPS at $0.09 and non-GAAP diluted EPS at $0.68.

How much did DXC spend on share repurchases?

DXC Technology repurchased shares worth $50 million as part of its ongoing commitment to return value to shareholders.

What did the CEO say about the quarter's performance?

CEO Raul Fernandez highlighted that the results met guidance limits for revenue growth and adjusted EBIT margin, with a strong focus on embedding AI in their solutions.

What is the projected revenue for DXC in fiscal year 2026?

DXC expects total revenue to be between $12.61 billion and $12.87 billion for the full fiscal year 2026.

Which segments performed the best in the latest report?

The Insurance Services segment showed revenue growth of 5.4% year over year, while the Consulting and Engineering Services segment had the highest segment profit margin despite revenue declines.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Fluence Energy Faces Leadership Departures Amid Legal Woes

Updated Category News Views 106

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Continue Reading
Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Updated Category News Views 99

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Continue Reading
Gaine Expands Healthcare Data Solutions Ahead of HLTH 2026

Updated Category News Views 227

Ever felt like healthcare systems are still stuck in a bygone era, struggling with data flinging through the void? Well, Gaine Technology is throwing down its gauntlet to change that narrative. Successful in pharmaceuticals and life sciences, they're turbocharging their Consent and Preference Management solution across the vast, tangled web of healthcare markets just in...

Continue Reading
Manhattan Associates Faces Investigation by KSF Law Firm

Updated Category News Views 203

KSF Digs Into Manhattan Associates' Claims In the swirl of the financial world, you rarely see an investigation that doesn’t raise a few eyebrows. This time, it's Manhattan Associates, Inc. (NasdaqGS: MANH) squarely in the crosshairs of Kahn Swick & Foti, LLC (KSF), a pivotal player in securities litigation. You’ve got to wonder what dirt might be uncovered here,...

Continue Reading
Novo's Research Unlocks New Insights into Food Noise

Updated Category News Views 211

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 244

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Breakthrough T1D Pushes Global T1D Awareness Forward

Updated Category News Views 155

Shining a Light on T1D with Global Efforts In a world where a change in lifestyle can happen at the drop of a hat, Breakthrough T1D is making waves by expanding their global "See T1D" campaign in honor of World Diabetes Day. This isn't your run-of-the-mill awareness push—this is about propelling an understanding of what life truly entails for those living with type 1...

Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 138

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading
CARsgen's CAR-T Breakthrough on China's Insurance List

Updated Category News Views 136

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Continue Reading
Advanta's Game-Changer: Acquiring Misr Hytech to Expand in Africa

Updated Category News Views 193

Advanta's Strategic Move into Africa Alright, let's cut to the chase. Advanta is making a big splash with its acquisition of Misr Hytech, a move that's going to shake things up in Africa's agricultural sector. This isn't just another merger to gloss over with your morning coffee. We're talking about a deal that's supposed to wrap up by January 31, 2027, bringing together...

Continue Reading

Top 5 Most Recently Viewed Articles

CNX Resources Reveals Third Quarter Results and Upcoming Call

Updated Category News Views 36

CNX Resources Corporation Financial Update CNX Resources Corporation (NYSE: CNX) is gearing up to announce its financial outcomes for the third quarter of 2024. This announcement is scheduled for 6:45 a.m. Eastern Time on a Thursday morning toward the end of October. During this time, CNX will also share essential materials, including remarks prepared for the quarter,...

Continue Reading
MBZUAI Enhances Research Collaboration with École Polytechnique

Updated Category News Views 183

Strengthening Research Cooperation Mohamed bin Zayed University of Artificial Intelligence (MBZUAI) has officially expanded its strategic partnership with École Polytechnique, aiming for a more profound collaboration in artificial intelligence (AI) research. This new Collaborative Research Agreement is a significant step towards enhancing research capabilities in both...

Continue Reading
Projected Growth of Marine Collagen: Key Insights and Trends

Updated Category News Views 152

The Growing Marine Collagen Market The marine collagen market is set to experience significant growth in the coming years. As consumer awareness around health and beauty continues to rise, we see a shift in preference towards marine collagen, thanks to its impressive bioavailability and sustainable sourcing methods. Recent analyses reveal that this sector is predicted to...

Continue Reading
BioLife Solutions Prepares for Q1 2025 Financial Disclosure

Updated Category News Views 144

Exciting Financial Insights Awaiting from BioLife Solutions BioLife Solutions, Inc. (NASDAQ: BLFS) has announced that it will disclose its first quarter 2025 financial results, marking an important update for investors and stakeholders alike. This revelation is set to occur after the market closes, creating anticipation among those closely monitoring the company’s...

Continue Reading
FuboTV Achieves Record Subscriber Growth in North America

Updated Category News Views 174

FuboTV Reports Unprecedented Subscriber Growth FuboTV (NYSE: FUBO) has recently made headlines as it recorded the highest-ever growth in its North American subscriber base. This achievement highlights the company’s potential in the competitive streaming industry. The stock saw a notable increase on the day the company announced its earnings for the third quarter....

Continue Reading